Excellence in clinical research from A to Z

Scroll down ⇩

About us

AtoZ-CRO GmbH is a full-service clinical research organisation (CRO) located in Overath near Cologne, Germany, with over 30 years of experience in clinical development and clinical study management. As a specialist for Germany, Europe, the US, and India, AtoZ-CRO offers a broad range of professional services and partner solutions for international clinical studies with pharmaceuticals and medical devices.


From its head office located in Overath, Germany, AtoZ-CRO manages and coordinates clinical studies of phase 0 through phase IV for national and international clients. The company forms a team of 35 highly experienced and dedicated industry professionals and medical specialists ensuring high standards in clinical study management. AtoZ-CRO is affiliated with a leading initiator of phase I studies in Warsaw, Poland.


Based on the company’s long-established international experience in clinical trial management and cooperation with high-rated business partners, AtoZ-CRO is proud to offer a broad range of services covering all clinical research needs, in particular for small and mid-sized pharmaceutical, biotech, and medical device companies.

Clinical Studies 

Contact us

Clinical Studies

Clinical Studies Phases 0 – IV

  • Planning of clinical studies
  • Preparation of study protocols
  • Design and implementation of CRFs (case report forms) and eCRFs
  • Processing of applications for ethical votes and permissions (e.g. CTA, IND)
  • Regulatory affairs issues
  • Legal EU representative

Other services

  • Monitoring
  • Post-marketing studies

-  NIS

-  PASS

-  Epidemiology

  • Pharmacovigilance
  • Biometry
  • Medical Writing and Translations

About us

Contact us

Contact us

AtoZ-CRO GmbH

Hauptstr. 77
51491 Overath
Tel: 02206 95 99 0
Fax: 02206 820 63
Email: info@atoz-cro.de
www.atoz-cro.de

Business Development

Alexa Foltin-Mertgen, M.Sc.
Email: a.foltin-mertgen@atoz-cro.de

Back to top ⇧

Go to article: Home | Taming the pharma beastGo to article: In this issueGo to article: Emirates SkyCargoGo to article: ContentsGo to article: TSS Company InsightGo to article: NewsGo to article: Daiichi JitsugyoGo to article: ICCI Company InsightGo to article: ICCIGo to article: The pharma industry briefingGo to article: Novo NordiskGo to article: Swiss WorldCargoGo to article: Understanding drug-resistant TBGo to article: CBDepot Company InsightGo to article: CBDepotGo to article: Through time: the breakthroughs that changed the course of HIV treatmentGo to article: Senn ChemicalsGo to article: Qatar AirwaysGo to article: Trouble at Teva: US price-fixing lawsuit adds to generic giant’s woesGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: The dangers of unlicensed stem cell clinicsGo to article: Komtur PharmaceuticalsGo to article: How do cancer cells communicate and can it help us catch them?Go to article: Verona’s ensifentrine: a potentially revolutionary treatment for COPDGo to article: Taming the pharma monster with Hedley ReesGo to article: Capsugel Company InsightGo to article: Altheria SolutionsGo to article: ‘Pay As You Go’ AI for drug discoveryGo to article: AtoZ-CRO GmbHGo to article: PharmaHempGo to article: Event: CPhl KoreaGo to article: EventsGo to article: Centaur Clinical | Company InsightGo to article: Centaur ClinicalGo to article: Next issueGo to article: Hapa Company InsightGo to article: Pfanstiehl